NEWS UPDATE
ABOUT US
Better Medicine
for a Brighter Tomorrow
‘Sol’ means the Sun and
‘Asia’ the Asian counties in Spanish.
We desire to be the Sun brightening the future of
various people facing many challenges of
cancers in Japan and other Asian countries.
Solasia
at a Glance
DEVELOPMENT STATUS
PRODUCTS
| PIPELINES | INDICATION | AREA | PRE- CLINICAL |
CLINIAL STUDY | NDA | APPROVAL /LAUNCH |
PROGRESS | PARTNER | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PHASE 1 | PHASE 2 | PHASE 3 | ||||||||
|
Sancuso®（SP-01） MORE INFO |
Chemotherapy Induced Nausea and Vomiting (CINV) | China |
|
|
|
|
|
|
Launched in 2019 | Solasia sales force: Beijing, Shanghai, Guangzhou
Lee’s Pharma: |
|
episil® oral liquid（SP-03） MORE INFO |
Pain associated oral mucositis [Medical Device] | Japan |
|
|
|
|
Launched in 2018 | Meiji Seika Pharma: Japan
Solasia sales force: Beijing, Shanghai, Guangzhou
Lee’s Pharma:
Synex： |
||
| China |
|
|
|
|
Launched in 2019 | |||||
| South Korea |
|
|
|
|
Launched in 2020 | |||||
PIPELINES
| PIPELINES | TARGET INDICATION |
AREA | PRE- CLINICAL |
CLINIAL STUDY | NDA | APPROVAL /LAUNCH |
PROGRESS | PARTNER | ||
|---|---|---|---|---|---|---|---|---|---|---|
| PHASE 1 | PHASE 2 | PHASE 3 | ||||||||
|
SP-02 MORE INFO |
Peripheral T-Cell Lymphoma (PTCL) | Japan |
|
|
|
|
|
|
Submitted NDA | Nippon Kayaku:
|
| South Korea, Taiwan, Hong Kong |
|
|
|
|
|
|
Pivotal PII study completion, preparation for NDA filing | |||
| China |
|
|
|
|
|
|
Phase II/III, preparation | |||
| US |
|
|
|
|
|
|
Phase IIA, completion | |||
| EU |
|
|
|
|
|
|
Phase II/III, preparation | |||
|
SP-04 MORE INFO |
Chemotherapy Induced Peripheral Neuropathy (CIPN) | Japan etc. |
|
|
|
|
|
|
Pre-clinical study in taxane-induced peripheral neuropathy | Maruho: |
|
SP-05 MORE INFO |
Colorectal Cancer (CRC) | Japan |
|
|
|
|
|
|
Global Phase III study | ー |
